Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
TB
MCID: MYC084
MIFTS: 68

Mycobacterium Tuberculosis 1 (TB)

Categories: Cardiovascular diseases, Endocrine diseases, Infectious diseases, Neuronal diseases, Rare diseases, Reproductive diseases, Respiratory diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Mycobacterium Tuberculosis 1

About this section

MalaCards integrated aliases for Mycobacterium Tuberculosis 1:

Name: Mycobacterium Tuberculosis 1 57
Tuberculosis 57 11 58 75 53 41 2 14 71 31 33
Tuberculosis, Susceptibility to 57 5
Tuberculoma 43 71
Mycobacterium Tuberculosis, Susceptibility to, 1 57
Mtbs1 57
Tb 47

Characteristics:


Prevelance:

Tuberculosis: 1-9/100000 (Greece, Iceland, Israel, Belgium, Austria, United States, Australia, France, Finland, Netherlands, Norway, Sweden, Denmark, Czech Republic, Germany, Italy, Europe) 1-5/10000 (Spain, Portugal, Poland, Latvia, Lithuania, Bosnia and Herzegovina, Croatia, Europe, Japan, Hungary, United Kingdom, Latin America, Ireland, Estonia, Turkey) 6-9/10000 (Algeria, Russian Federation, China, Ukraine) >1/1000 (Romania, Worldwide, India, South Africa) 58

Age Of Onset:

Tuberculosis: All ages 58

Classifications:

MalaCards categories:
Global: Infectious diseases Rare diseases
Anatomical: Reproductive diseases Respiratory diseases Endocrine diseases Cardiovascular diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 31 32
ICD11: 33
Orphanet: 58  
Rare infertility disorders
Rare respiratory diseases
Rare endocrine diseases
Rare infectious diseases


External Ids:

Disease Ontology 11 DOID:399
OMIM® 57 607949
MeSH 43 D014375
SNOMED-CT 68 15202009
ICD10 31 A15-A19
MESH via Orphanet 44 D014376
ICD10 via Orphanet 32 A15 A16 A17 more
UMLS via Orphanet 72 C0041296
Orphanet 58 ORPHA3389
UMLS 71 C0041295 C0041296
Sources

Summaries for Mycobacterium Tuberculosis 1

About this section

MedlinePlus: 41 What is tuberculosis (TB)? Tuberculosis (TB) is a bacterial disease that usually attacks the lungs. But it can also attack other parts of the body, including the kidneys, spine, and brain. Not everyone infected with TB bacteria (germs) becomes sick. So, there are two types of TB conditions: Latent TB infection, where the TB germs live in your body but don't make you sick. TB disease (active TB) where you get sick from the TB germs. TB disease can almost always be cured with antibiotics. But if it's not treated properly, it can be fatal. TB is found in the U.S., but it is more common in certain other countries. What causes tuberculosis (TB)? TB is caused by bacteria (germs) called Mycobacterium tuberculosis. The germs spread from person to person through the air. People who have TB disease in their throat or lungs spread the germs in the air when they cough, sneeze, talk, or sing. If you breathe in the air that has the germs, you can get TB. TB is not spread by touching, kissing, or sharing food or dishes. You're more likely to catch TB from people you live or work with than from people you see for shorter amounts of time. Who is more likely to get infected with tuberculosis (TB) germs? Anyone who is near a person with TB disease can get infected with the germs. You are more likely to be near someone with TB disease if you: Were born in or often travel to countries where TB disease is common Are a health care worker Work or live in a place where TB is more common, such as shelters for people without homes, jails, and nursing homes Who is more likely to develop TB disease? Certain people are more likely to get sick with TB disease after they get infected. They include people who: Have HIV/AIDS Became infected with TB in the last 2 years Have other diseases, such as diabetes, that make it hard for your body to fight TB germs Have alcohol use disorder or inject illegal drugs Were not treated correctly for TB in the past Are under age 5 Are an older adult What are the symptoms of tuberculosis (TB)? Most people who have TB germs in their bodies don't get sick with TB disease. Instead, they have latent TB infection. With a latent TB infection, you: Don't have symptoms Can't spread TB to others Could get sick with active TB disease in the future if your immune system becomes weak for another reason Need to take medicine to prevent getting sick with active TB disease in the future If you have TB disease, the TB germs are active, meaning that they are growing (multiplying) inside your body and making you sick. If the TB is growing in your lungs or throat, you can spread the TB germs to other people. You can get sick with TB disease weeks to years after you're infected with TB germs. With TB disease, your symptoms will depend on where the TB is growing in your body General symptoms may include: Chills and fever Night sweats (heavy sweating during sleep) Losing weight without trying Loss of appetite Weakness or fatigue Symptoms from TB disease in your lungs may include: A cough that lasts longer than 3 weeks Coughing up blood or sputum (a thick mucus from the lungs) Chest pain How is tuberculosis (TB) diagnosed? Your health care provider or your local health department can test you to find out if you have TB germs in your body. They will give you either a TB skin or blood test. If your test shows that you have TB germs, you'll need to have other tests to see if the germs are actively growing: Tests for TB disease in the lungs usually include testing samples of your sputum and having chest x-rays. Tests for TB disease in other parts of your body may include tests of urine and tissue samples. You may need a TB test if you have symptoms of TB disease or if you are at high risk because you are more likely to be near someone with TB disease. What is the treatment for tuberculosis (TB)? The treatment for both latent TB infection and TB disease is antibiotics. To make sure you get rid of all the TB germs in your body, it's very important to follow the directions for taking your medicine. If you don't follow the directions, the TB germs in your body could change and become antibiotic resistant. That means the medicine may stop working and your TB may become hard to cure. For latent TB infections, you usually take medicines for 3 to 9 months. Treatment helps make sure you don't get TB disease in the future. For active TB disease, you usually need to take medicines for 6 to 12 months. Treatment will almost always cure you if you take your pills the right way. For TB disease in your lungs or throat, you'll need to stay home for a few weeks, so you don't spread disease to other people. You can protect the people you live with by: Covering your nose and mouth. Opening windows when possible. Not getting too close to them. By following medical advice for TB testing and treatment, you can keep yourself healthy and help stop the spread of TB. Centers for Disease Control and Prevention

MalaCards based summary: Mycobacterium Tuberculosis 1, also known as tuberculosis, is related to pulmonary tuberculosis and miliary tuberculosis, and has symptoms including fever, pruritus and snoring. An important gene associated with Mycobacterium Tuberculosis 1 is MTBS1 (Mycobacterium Tuberculosis, Susceptibility To Infection By, 1), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Calcium carbonate and Etanercept have been mentioned in the context of this disorder. Affiliated tissues include lungs, lymph nodes and pericardium, and related phenotypes are fatigue and fever

CDC: 2 Tuberculosis (TB) is caused by a bacterium called Mycobacterium tuberculosis. The bacteria usually attack the lungs, but TB bacteria can attack any part of the body such as the kidney, spine, and brain. Not everyone infected with TB bacteria becomes sick. As a result, two TB-related conditions exist: latent TB infection (LTBI) and TB disease. If not treated properly, TB disease can be fatal.

Orphanet: 58 Tuberculosis (TB) is a contagious-infectious disease caused mainly by Mycobacterium tuberculosis that in most individuals is usually asymptomatic but that in at risk individuals (e.g. with diabetes or with HIV infection) can cause weakness, fever, weight loss, night sweat, and respiratory anomalies such as chronic cough, chest pain, hemoptysis or respiratory insufficiency.

Disease Ontology: 11 A primary bacterial infectious disease that is located in lungs, located in lymph nodes, located in pericardium, located in brain, located in pleura or located in gastrointestinal tract, has material basis in Mycobacterium tuberculosis, which is transmitted by droplets released into the air when an infected person coughs or sneezes.

Wikipedia: 75 Tuberculosis (TB) is an infectious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria.... more...

More information from OMIM: 607949
Sources

Related Diseases for Mycobacterium Tuberculosis 1

About this section

Diseases in the Mycobacterium Tuberculosis 1 family:

Mycobacterium Tuberculosis 2 Mycobacterium Tuberculosis 3

Diseases related to Mycobacterium Tuberculosis 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2633)
# Related Disease Score Top Affiliating Genes
1 pulmonary tuberculosis 33.7 TNF TLR2 SLC11A1 INHA IL4 IL10
2 miliary tuberculosis 33.7 TNF IL4 IL10 IFNGR1 IFNG ADA
3 multidrug-resistant tuberculosis 33.4 TNF INHA IL10 IFNG HSPD1
4 extrapulmonary tuberculosis 33.3 TNF TLR2 SLC11A1 IL4 IL17A IL10
5 urogenital tuberculosis 33.3 SLC11A1 IFNG ADA
6 pleural tuberculosis 33.2 TNF IFNG ADA
7 abdominal tuberculosis 33.2 TNF IFNG ADA
8 gastrointestinal tuberculosis 33.2 TNF IFNG ADA
9 lymph node tuberculosis 33.1 TNF IFNG ADA
10 intestinal tuberculosis 33.1 TNF IFNG ADA
11 central nervous system tuberculosis 33.0 TNF IFNG ADA
12 laryngeal tuberculosis 33.0 SLC11A1 IFNG
13 pericardial tuberculosis 32.9 TNF IFNG ADA
14 bladder tuberculosis 32.8 IFNG ADA
15 esophageal tuberculosis 32.7 IFNG ADA
16 tuberculous peritonitis 32.6 IFNG ADA
17 lung disease 32.6 TNF TLR2 SLC11A1 IL10 IFNGR1 IFNG
18 aspergillosis 32.6 TNF TLR2 IL4 IL10 IFNG CD209
19 silicosis 32.4 TNF IL4 IL17A IL10
20 immune deficiency disease 32.4 TNF TLR2 IL4 IL17A IL10 IFNGR1
21 acquired immunodeficiency syndrome 32.3 TNF IL10 IFNG ADA
22 lymphadenitis 32.2 TNF SLC11A1 IL10 IFNGR1 IFNG CD209
23 melioidosis 32.2 TNF TLR2 IL10 IFNG
24 sarcoidosis 1 32.2 TNF SLC11A1 IL17A IL10 IFNG ADA
25 leprosy 3 32.1 TNF TLR2 SLC11A1 IL4 IL17A IL10
26 meningitis 32.1 TNF TLR2 IL4 IL17A IL10 IFNG
27 respiratory failure 32.0 TNF IL4 IL17A IL10 IFNG
28 crohn's disease 32.0 TNF TLR2 IL4 IL17A IL10 IFNG
29 pleurisy 31.9 TNF IFNG ADA
30 spondylitis 31.9 TNF IL17A IL10 IFNG
31 diabetes mellitus 31.9 TNF TLR2 IL4 IL17A IL10 IFNG
32 peritonitis 31.9 TNF TLR2 IL17A IL10 IFNG ADA
33 pneumonia 31.9 TNF TLR2 IL4 IL17A IL10 IFNG
34 uveitis 31.9 TNF IL4 IL17A IL10 IFNG HSPD1
35 osteomyelitis 31.9 TNF TLR2 IL4 IL10 IFNGR1 IFNG
36 viral infectious disease 31.8 TNF TLR2 IL4 IL17A IL10 IFNG
37 macs syndrome 31.8 TNF SLC11A1 IL10 IFNGR1 IFNG HSPD1
38 bronchiectasis 31.8 TNF TLR2 IFNG
39 allergic disease 31.8 TNF IL4 IL17A IL10 IFNG
40 vasculitis 31.7 TNF IL17A IL10 HSPD1
41 mikulicz disease 31.7 IL4 IL10
42 bronchitis 31.7 TNF TLR2 IL4 IL10
43 malaria 31.7 TNF TLR2 MAPKAPK3 IL4 IL17A IL10
44 spondyloarthropathy 1 31.7 TNF IL17A IL10 HSPD1
45 syphilis 31.7 TNF TLR2 IL17A CD209
46 pericarditis 31.7 TNF IFNG ADA
47 asthma 31.7 TNF TLR2 IL4 IL17A IL10 IFNG
48 brucellosis 31.6 TNF SLC11A1 IL4 IL17A IL10 IFNG
49 lymphopenia 31.6 IL4 IL10 IFNG ADA
50 choroiditis 31.6 TNF IL17A IL10 IFNG

Graphical network of the top 20 diseases related to Mycobacterium Tuberculosis 1:



Diseases related to Mycobacterium Tuberculosis 1
Sources

Symptoms & Phenotypes for Mycobacterium Tuberculosis 1

About this section

Human phenotypes related to Mycobacterium Tuberculosis 1:

58 30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 58 30 Frequent (33%) Frequent (79-30%)
 HP:0012378
2 fever 58 30 Frequent (33%) Frequent (79-30%)
 HP:0001945
3 cough 58 30 Frequent (33%) Frequent (79-30%)
 HP:0012735
4 weight loss 58 30 Frequent (33%) Frequent (79-30%)
 HP:0001824
5 abnormal lung morphology 58 30 Frequent (33%) Frequent (79-30%)
 HP:0002088

Clinical features from OMIM®:

607949 (Updated 08-Dec-2022)

UMLS symptoms related to Mycobacterium Tuberculosis 1:


fever; pruritus; snoring; coughing

MGI Mouse Phenotypes related to Mycobacterium Tuberculosis 1:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.11 ADA CISH IFNG IFNGR1 IL10 IL17A
2 immune system MP:0005387 10.1 ADA CD209 CD244 CISH IFNG IFNGR1
3 liver/biliary system MP:0005370 10.06 ADA IFNG IFNGR1 IL10 IL17A IL4
4 digestive/alimentary MP:0005381 10.06 ADA CD209 IFNG IFNGR1 IL10 IL17A
5 neoplasm MP:0002006 9.98 IFNG IFNGR1 IL10 INHA SLC11A1 TLR2
6 hematopoietic system MP:0005397 9.83 ADA CD209 CD244 CISH HSPD1 IFNG
7 respiratory system MP:0005388 9.81 ADA CISH HSPD1 IFNG IL10 IL17A
8 integument MP:0010771 9.32 HSPD1 IFNG IFNGR1 IL10 IL17A IL4
Sources

Drugs & Therapeutics for Mycobacterium Tuberculosis 1

About this section

Drugs for Mycobacterium Tuberculosis 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 372)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Calcium carbonate Approved, Investigational Phase 4 471-34-1
2
Etanercept Approved, Investigational Phase 4 185243-69-0
3
Tofacitinib Approved, Investigational Phase 4 477600-75-2 9926791
4
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
5
Artemether Approved Phase 4 71963-77-4 68911 9796294
6
Lumefantrine Approved Phase 4 82186-77-4 6437380
7
Abacavir Approved, Investigational Phase 4 136470-78-5, 188062-50-2 441300
8
Zidovudine Approved Phase 4 30516-87-1 35370
9
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
10
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
11
Sulfamethoxazole Approved Phase 4 723-46-6 5329
12
BCG vaccine Approved, Investigational Phase 4
13
Racivir Approved, Investigational Phase 4 143491-57-0, 143491-54-7 60877
14
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
15
Nelfinavir Approved Phase 4 159989-64-7 64143
16
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715
17
Dapsone Approved, Investigational Phase 4 80-08-0 2955
18
Dolutegravir Approved Phase 4 1051375-16-6 57414794 54726191
19
Pyrazinamide Approved, Investigational Phase 4 98-96-4 1046
20
Bedaquiline Approved Phase 4 843663-66-1 5388906
21
Clofazimine Approved, Investigational Phase 4 2030-63-9 2794
22
Clarithromycin Approved Phase 4 81103-11-9 84029
23
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
24
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
25
Streptomycin Approved, Vet_approved Phase 4 57-92-1 19649
26
Capreomycin Approved Phase 4 11003-38-6
27
Gatifloxacin Approved, Investigational, Withdrawn Phase 4 112811-59-3 5379
28
Clavulanic acid Approved, Vet_approved Phase 4 58001-44-8 5280980
29
Methadone Approved Phase 4 76-99-3, 1095-90-5 4095
30
Meropenem Approved, Investigational Phase 4 119478-56-7, 96036-03-2 441130
31
Azithromycin Approved Phase 4 83905-01-5 447043
32
Cilastatin Approved, Investigational Phase 4 82009-34-5 6435415
33
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7, 53152-21-9 644073 40400
34
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
35
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
36
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
37
Aldesleukin Approved Phase 4 110942-02-4
38
Zoledronic acid Approved Phase 4 118072-93-8 68740
39
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
40
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
41
Nevirapine Approved Phase 4 129618-40-2 4463
42
Lopinavir Approved Phase 4 192725-17-0 92727
43
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
44
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
45
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
46 Artemether, Lumefantrine Drug Combination Phase 4
47 Antiprotozoal Agents Phase 4
48 Antiparasitic Agents Phase 4
49 Vitamins Phase 4
50 Trace Elements Phase 4

Interventional clinical trials:

(show top 50) (show all 1252)
# Name Status NCT ID Phase Drugs
1 Phase IV Study of the Quantiferon-RD1 Test Unknown status NCT00311220 Phase 4 tuberculin for skin test
2 The Study of Standardized Preoperative Anti-tuberculosis Treatment of Surgical Treatment of Spinal Tuberculosis Patients Unknown status NCT02477852 Phase 4 Isoniazid;Rifampicin;Ethambutol;Pyrazinamide
3 Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults Unknown status NCT01782950 Phase 4 Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
4 Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach Unknown status NCT01875952 Phase 4 Isoniazid
5 The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis Unknown status NCT02588196 Phase 4 Dexamethasone acetate
6 New Super-short Course Regimen for Retreatment Pulmonary Tuberculosis Unknown status NCT02331823 Phase 4 Isoniazid Aminosalicylate Tablets;Streptomycin injectable
7 Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis in the National Institute of Respiratory Diseases Unknown status NCT02464683 Phase 4
8 The Impact of the Simple Verbal Intervention for Adequately Collecting Sputum and the Acceptable Specimen Based on Gram Stain, on the Results of Sputum Acid-fast Bacilli Smear Testing Unknown status NCT01135043 Phase 4
9 International Multicenter Trial for the Evaluation of a Four-Drug Fixed Dose Combined Tablet Daily in the Initial Intensive Phase of Chemotherapy Followed by a Two-Drug Fixed Dose Combined Tablet Three Times a Week in the Continuation Phase for the Treatment of Pulmonary Tuberculosis Unknown status NCT00216333 Phase 4 combined fixed dose combination
10 Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis (EVIDENT Study): a Randomized, Double Blind, Controlled Trial Unknown status NCT02169570 Phase 4
11 Different Reintroduction Regimens of Antituberculosis Drugs After Development of Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
12 Shortened Regimens for First Diagnosed Smear Positive Drug Susceptible Pulmonary Tuberculosis: a Randomised Controlled Non-inferiority Trial Unknown status NCT02901288 Phase 4 Isoniazid;Rifampicin;Pyrazinamide;Ethambutol;Levofloxacin
13 Randomized, Controlled Trial Comparing Efficacy of Percutaneous and Intradermal Vaccination With Japanese (Tokyo) 172 BCG in the Prevention of Tuberculosis In Infants Vaccinated at Birth Unknown status NCT00242047 Phase 4
14 Risk of Tuberculosis and Infections in Spondyloarthritis Patients Treated With Tofacitinib in Bangladesh Unknown status NCT03504072 Phase 4 Tofacitinib 5 mg,;Etanercept
15 Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
16 The Application of the N-acetyltransferase 2 (NAT2) Genotyping in Re-challenge Protocol of Isoniazid (INH) Titration in Patients With Anti-TB Medications-induced Hepatitis Unknown status NCT00728546 Phase 4 Isoniazid (Rifinah)
17 Pharmacokinetic Interaction Between Coartem® and Either Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4 Lumefantrine-artemether and nevirapine;lumefantrine-artemether and efavirenz;Lumefantrine-artemether and rifampicin
18 Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
19 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
20 The Pharmacokinetic Effect of Clarithromycin on the AUC0-12h of Linezolid in Multidrug-resistant and Extensively Drug-resistant Tuberculosis (MDR/XDR-TB) Patients Completed NCT01521364 Phase 4 Addition of different doses of clarithromycin.
21 A Pilot Study Of Open-Label Fixed Dose Combination Zidovudine/Lamivudine/Abacavir In HIV-Infected Persons With Tuberculosis In Moshi, Tanzania; Tuberculosis And HIV Immune Reconstitution Syndrome Trial (THIRST) Completed NCT00851630 Phase 4 Fixed dose combination zidovudine/lamivudine/abacavir
22 Evaluation of Three Regimens of Chemoprophylaxis for Tuberculosis in Patients co-Infected by HIV and Mycobacterium Tuberculosis Completed NCT00402454 Phase 4 isoniazid, rifampin + isoniazid or rifampin + pyrazinamide
23 A Randomised Control Trial on the Effectiveness of Three Modalities of Tuberculosis Treatment Supervision Under DOTS Strategy in Ethiopia. Completed NCT00939419 Phase 4
24 Evaluation of 2 Interferon γ Assays (QuantiFERON TB Gold In-Tube® and T-SPOT.TB®) in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT Completed NCT00647205 Phase 4
25 Multicenter Open Non-Comparative Clinical Study to Evaluate the Efficacy and Safety of Three Months TAVANIC Course (Levofloxacin) in Combine Treatment of Multi-Drug-Resistant Tuberculosis (MDR-TB) Completed NCT00495339 Phase 4 Levofloxacin
26 The Effect of New MDR-TB Regimen With 18 Month Duration Containing 6 Anti-tuberculosis Drugs Completed NCT03830671 Phase 4 18-month regimen containing 6 anti-TB drugs
27 Cost-effectiveness of Quantiferon Gold in VITRO Test of T-lymphocytic Response for Detection of Latent Tuberculosis in At-risk Healthcare Workers Completed NCT00797836 Phase 4
28 Pilot Clinical Trial of PRS TB Regimen I - Phase II Completed NCT03561753 Phase 4 Group A (the standard 2HRZE/4HR regimen）;Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)
29 Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT) Completed NCT00298870 Phase 4 Isoniazid;isoniazed
30 Drugs for Treatment of Latent Tuberculosis Infection Objective 4: Identify Biomarkers for Clinical Trials of Drugs Active Against Latent TB Completed NCT00293228 Phase 4 Isoniazid;isoniazid
31 Comparison of Two Strategies for Therapeutic Decision-making in Tuberculosis Contact Tracing: a Standard Strategy Based on Tuberculin Skin Test (TST) Alone vs TST Combined With QuantiFERON®-TB Gold In-Tube (QFT-IT) Completed NCT01223534 Phase 4 Preventive treatment with Isoniazid.;Preventive treatment with Isoniazid
32 Pilot Roll Out of the Xpert MTB/Rif for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil: a Stepped Wedge Trial Completed NCT01363765 Phase 4
33 Investigation of a Novel Approach to Improve Adherence to Treatment and Treatment Success Rates for Tuberculosis Patients in Senegal Completed NCT00412009 Phase 4
34 An Evaluation of the Pharmacological Interaction of Lopinavir 800mg - Ritonavir 200mg Combination and Rifampin in Subjects Presenting Tuberculosis, With Contraindication for Antiretroviral Regimens Including Efavirenz Completed NCT00771498 Phase 4 Lopinavir
35 A Pilot Clinical Trial Characterizing Use of Ingestion Sensor Enabled Rifamate in Comparison to Directly Observed Therapy for the Treatment of Tuberculosis Completed NCT01960257 Phase 4
36 Systematic Empirical vs. Test-guided Anti-tuberculosis Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating Antiretroviral Therapy With CD4 Cell Counts <100/mm3: the STATIS Randomized Controlled Trial Completed NCT02057796 Phase 4 ART (Atripla, Truvada, Efavirenz, Combivir);Rifampin, isoniazid, pyrazinamide, ethambutol
37 Comparison of Quantiferon-TB Gold Assay With Tuberculin Skin Testing for Detecting Latent Mycobacterium Tuberculosis Infection in Patients With Chronic Liver Disease Awaiting Liver Transplantation Completed NCT00402402 Phase 4
38 A Randomized Trial of Three Regimens to Prevent Tuberculosis in HIV-Infected Patients With Anergy Completed NCT00402610 Phase 4 isoniazid, rifampin + isoniazid, rifampin + pyrazinamide or not treatment
39 A Randomized, Placebo-Controlled Study of Limited vs. Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana Completed NCT00164281 Phase 4 Isoniazid
40 A Strategy Study of Immediate Versus Deferred Initiation of Antiretroviral Therapy for AIDS Disease-Free Survival in HIV-Infected Persons Treated for Tuberculosis With CD4 Less Than 250 Cells/mm^3 Completed NCT00108862 Phase 4
41 TBTC Study 23B:Intensive Pharmacokinetics of the Nelfinavir Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen Completed NCT00023400 Phase 4 Nelfinavir;Rifabutin
42 A Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-Infected Women in High Tuberculosis (TB) Incidence Settings Completed NCT01494038 Phase 4 Isoniazid (INH);Placebo for isoniazid (INH)
43 Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation: a National Multicenter Randomized Clinical Trial Completed NCT02231229 Phase 4 conventional therapy
44 Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens (REMEMBER) Completed NCT01380080 Phase 4 Atripla (r);Efavirenz;Truvada;Rifampin/isoniazid/pyrazinamide/ethambutol FDC;Rifampin/isoniazid FDC;Isoniazid
45 Effect of HIV and/or Active Tuberculosis on the Humoral and Cell Mediated Immune Responses to Un-adjuvanted Trivalent Sub-unit Influenza Vaccine (TIV) in Adults Completed NCT01811823 Phase 4
46 Acceptability and Completion Rates of a New 12 Dose Treatment (3 Month) Compared to the Standard Treatment for Latent TB Infection Treatment Completed NCT02689089 Phase 4 3HP
47 URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence Completed NCT03302299 Phase 4 Isoniazid 300 Mg ORAL TABLET;Pyridoxine 25 Mg Oral Tablet
48 Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Antituberculosis Treatment Induced Hepatotoxicity Completed NCT00405301 Phase 4 Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day)
49 Feasibility and Effectiveness of Community Based Isoniazid Preventive Therapy in Kenya Completed NCT00850915 Phase 4
50 Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study) Completed NCT01637558 Phase 4 8 hourly LPV/r during TB treatment;Nevirapine;Lopinavir/Ritonavir

Search NIH Clinical Center for Mycobacterium Tuberculosis 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


aminosalicylic acid
Antitubercular Agents
Ethambutol
Ethambutol Hydrochloride
Ethionamide
isoniazid
Pyrazinamide

Cochrane evidence based reviews: tuberculoma

Sources

Genetic Tests for Mycobacterium Tuberculosis 1

About this section
Sources

Anatomical Context for Mycobacterium Tuberculosis 1

About this section

Organs/tissues related to Mycobacterium Tuberculosis 1:

FMA: Lungs, Lymph Nodes, Pericardium, Brain, Pleura, Gastrointestinal Tract
MalaCards : Skin, Kidney, Lung, Brain, T Cells, Whole Blood, Lymph Node
Sources

Publications for Mycobacterium Tuberculosis 1

About this section

Articles related to Mycobacterium Tuberculosis 1:

(show top 50) (show all 30840)
# Title Authors PMID Year
1
Linkage of tuberculosis to chromosome 2q35 loci, including NRAMP1, in a large aboriginal Canadian family. 53 62 57
10882571 2000
2
CISH and susceptibility to infectious diseases. 5
20484391 2010
3
Can digital adherence technologies reduce inequity in tuberculosis treatment success? Evidence from a randomised controlled trial. 41
36455988 2022
4
INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial. 41
36356989 2022
5
CROI 2022: tuberculosis and infectious complications in persons With HIV. 41
36347059 2022
6
Lactic acid bacteria enhance autophagic ability of mononuclear phagocytes by increasing Th1 autophagy-promoting cytokine (IFN-gamma) and nitric oxide (NO) levels and reducing Th2 autophagy-restraining cytokines (IL-4 and IL-13) in response to Mycobacterium tuberculosis antigen. 53 62
20381647 2010
7
Microsatellite polymorphisms in intron 2 of the toll-like receptor 2 gene and their association with susceptibility to pulmonary tuberculosis in Han Chinese. 53 62
20298136 2010
8
Identification of Mycobacterium tuberculosis clinical isolates in Bangladesh by a species distinguishable multiplex PCR. 53 62
20470432 2010
9
A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis. 53 62
20200152 2010
10
Biochemical and structural characterization of Mycobacterium tuberculosis beta-lactamase with the carbapenems ertapenem and doripenem. 53 62
20353175 2010
11
Toll-like receptors 2 and 4 gene polymorphisms in a southeastern Chinese population with tuberculosis. 53 62
20002809 2010
12
The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. 53 62
20305661 2010
13
Suprastructures and dynamic properties of Mycobacterium tuberculosis FtsZ. 53 62
20139085 2010
14
Rapid detection of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis by high-resolution melting analysis. 53 62
20164280 2010
15
Mycobacterium tuberculosis infection induces il12rb1 splicing to generate a novel IL-12Rbeta1 isoform that enhances DC migration. 53 62
20212068 2010
16
Using epitope predictions to evaluate efficacy and population coverage of the Mtb72f vaccine for tuberculosis. 53 62
20353587 2010
17
Analysis of rpsL and rrs mutations in Beijing and non-Beijing streptomycin-resistant Mycobacterium tuberculosis isolates from Singapore. 53 62
19519851 2010
18
T cells co-producing Mycobacterium tuberculosis-specific type 1 cytokines for the diagnosis of latent tuberculosis. 53 62
20146988 2010
19
IL-10 and IL-12 production in response to Mycobacterium tuberculosis total lipid antigens in multidrug resistant tuberculosis. 53 62
20371920 2010
20
Experimental tuberculosis: designing a better model to test vaccines against tuberculosis. 53 62
20188631 2010
21
Protein kinase and phosphatase signaling in Mycobacterium tuberculosis physiology and pathogenesis. 53 62
19766738 2010
22
Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. 53 62
20112395 2010
23
Association of reduced tumor necrosis factor alpha, gamma interferon, and interleukin-1beta (IL-1beta) but increased IL-10 expression with improved chest radiography in patients with pulmonary tuberculosis. 53 62
20007364 2010
24
Vitamin D receptor genetic polymorphisms and tuberculosis: updated systematic review and meta-analysis. 53 62
20003690 2010
25
The Mycobacterium tuberculosis cytochrome P450 system. 53 62
19635450 2010
26
DC-SIGN and mannosylated surface structures of Mycobacterium tuberculosis: a deceptive liaison. 53 62
19892432 2010
27
TNF in host resistance to tuberculosis infection. 53 62
20173394 2010
28
Performance of the tuberculin skin test and interferon-gamma release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population. 53 62
20003535 2009
29
Induction of Th1/Th17 immune response by Mycobacterium tuberculosis: role of dectin-1, Mannose Receptor, and DC-SIGN. 53 62
19773555 2009
30
Infection with Mycobacterium tuberculosis Beijing genotype strains is associated with polymorphisms in SLC11A1/NRAMP1 in Indonesian patients with tuberculosis. 53 62
19863441 2009
31
CCL2 responses to Mycobacterium tuberculosis are associated with disease severity in tuberculosis. 53 62
20041183 2009
32
Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy. 53 62
19874177 2009
33
IFNgamma response to Mycobacterium tuberculosis, risk of infection and disease in household contacts of tuberculosis patients in Colombia. 53 62
20011589 2009
34
IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion. 53 62
19864591 2009
35
Effect of 1, 25 dihydroxyvitamin D(3) on matrix metalloproteinases MMP-7, MMP-9 and the inhibitor TIMP-1 in pulmonary tuberculosis. 53 62
19615945 2009
36
BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay. 53 62
19715782 2009
37
Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori. 53 62
19718030 2009
38
CCR2, MCP-1, SDF-1a & DC-SIGN gene polymorphisms in HIV-1 infected patients with & without tuberculosis. 53 62
19942750 2009
39
Isoniazid and rifampicin resistance-associated mutations in Mycobacterium tuberculosis isolates from Yangon, Myanmar: implications for rapid molecular testing. 53 62
19710078 2009
40
Structural basis for the inhibition of Mycobacterium tuberculosis glutamine synthetase by novel ATP-competitive inhibitors. 53 62
19695264 2009
41
Toll-like receptor 2 and DC-SIGNR1 differentially regulate suppressors of cytokine signaling 1 in dendritic cells during Mycobacterium tuberculosis infection. 53 62
19617348 2009
42
Interaction of Mycobacterium tuberculosis CYP130 with heterocyclic arylamines. 53 62
19605350 2009
43
Association of SLC11A1 with tuberculosis and interactions with NOS2A and TLR2 in African-Americans and Caucasians. 53 62
19723394 2009
44
Functionalized 3-amino-imidazo[1,2-a]pyridines: a novel class of drug-like Mycobacterium tuberculosis glutamine synthetase inhibitors. 53 62
19560924 2009
45
Differential cytokine/chemokines and KL-6 profiles in patients with different forms of tuberculosis. 53 62
19570688 2009
46
The NRAMPI, VDR and TNF-alpha gene polymorphisms in Iranian tuberculosis patients: the study on host susceptibility. 53 62
20231985 2009
47
1alpha,25-dihydroxyvitamin D3 inhibits matrix metalloproteinases induced by Mycobacterium tuberculosis infection. 53 62
19178594 2009
48
Multiplex PCR assay for simultaneous detection and differentiation of Mycobacterium tuberculosis, Mycobacterium avium complexes and other Mycobacterial species directly from clinical specimens. 53 62
19302308 2009
49
Genetic association between a chemokine gene CXCL-10 (IP-10, interferon gamma inducible protein 10) and susceptibility to tuberculosis. 53 62
19523460 2009
50
TLR2 polymorphisms, Arg753Gln and Arg677Trp, are not associated with increased burden of tuberculosis in Indian patients. 53 62
19686607 2009
Sources

Variations for Mycobacterium Tuberculosis 1

About this section

ClinVar genetic disease variations for Mycobacterium Tuberculosis 1:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CISH, MAPKAPK3 NM_001243926.2(MAPKAPK3):c.-436A>T SNV Risk Factor
 7091 rs414171 GRCh37: 3:50649499-50649499
GRCh38: 3:50612068-50612068
Sources

Expression for Mycobacterium Tuberculosis 1

About this section
Search GEO for disease gene expression data for Mycobacterium Tuberculosis 1.
Sources

Pathways for Mycobacterium Tuberculosis 1

About this section


Pathways directly related to Mycobacterium Tuberculosis 1:

(show all 19)
# Pathway Source
1 Response of Mtb to phagocytosis Reactome 66
2 Prevention of phagosomal-lysosomal fusion Reactome 66
3 Infection with Mycobacterium tuberculosis Reactome 66
4 Suppression of phagosomal maturation Reactome 66
5 Suppression of apoptosis Reactome 66
6 Manipulation of host energy metabolism Reactome 66
7 Mtb iron assimilation by chelation Reactome 66
8 Latent infection - Other responses of Mtb to phagocytosis Reactome 66
9 Inhibition of nitric oxide production Reactome 66
10 Modulation by Mtb of host immune system Reactome 66
11 Tolerance by Mtb to nitric oxide produced by macrophages Reactome 66
12 Blockage of phagosome acidification Reactome 66
13 Cell redox homeostasis Reactome 66
14 Tolerance of reactive oxygen produced by macrophages Reactome 66
15 Antimicrobial action and antimicrobial resistance in Mtb Reactome 66
16 Inhibition of membrane repair Reactome 66
17 Suppression of autophagy Reactome 66
18 Phagocyte cell death caused by cytosolic Mtb Reactome 66
19 Escape of Mtb from the phagocyte Reactome 66

Pathways related to Mycobacterium Tuberculosis 1 according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.89 CD1B CD209 CISH GNLY IFNG IFNGR1
2
TGF-Beta Pathway 64
Show member pathways
 13.48 TNF MAPKAPK3 IL4 IL17A IL10 IFNGR1
3
Cytokine Signaling in Immune system 66
Show member pathways
 13.27 TNF MAPKAPK3 IL4 IL17A IL10 IFNGR1
4
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.59 TNF IL4 IL17A IL10 IFNGR1 IFNG
5
NF-kappaB Signaling 3
12.46 CISH IFNG IL10 IL17A IL4 TLR2
6
Bacterial infections in CF airways 22
Show member pathways
 12.37 TNF TLR2 IL4 IFNGR1 IFNG
7
Colorectal Cancer Metastasis 64
12.14 TNF TLR2 IFNGR1 IFNG
8
T-cell activation SARS-CoV-2 74
Show member pathways
 12.12 TNF IL4 IL17A IL10 IFNG
9
Neuroinflammation and glutamatergic signaling 74
12.05 TNF IL4 IL10 IFNGR1 IFNG
10
Interleukin-4 and Interleukin-13 signaling 66
11.93 IL10 IL17A IL4 TNF
11
Hematopoietic Stem Cells and Lineage-specific Markers 65
11.91 TNF IL4 IL10 IFNG CD244 CD209
12
Th17 Differentiation 65
Show member pathways
 11.83 IFNG IL17A IL4 TLR2
13
IL27-mediated signaling events 61
Show member pathways
 11.8 TNF TLR2 IL17A IL10 IFNGR1 IFNG
14
Activation of NF-KappaB by PKR 64
Show member pathways
 11.73 TNF IFNGR1 IFNG
15
Extrafollicular B cell activation by SARS-CoV-2 74
11.71 TNF IL4 IL10 IFNG
16
Dendritic Cells Developmental Lineage Pathway 65
11.7 TNF IL10 IFNG CD244 CD209
17
Allograft rejection 74
11.7 TNF IL4 IL17A IL10 IFNG GNLY
18
Th17 cell differentiation pathway 74
11.69 IL4 IL17A IFNGR1 IFNG
19
AP-1 transcription factor network 61
11.66 IL4 IL10 IFNG
20
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 61
Show member pathways
 11.64 TNF IL4 IFNG
21
Innate Lymphoid Cells Differentiation 65
11.54 TNF IL4 IL17A IL10 IFNG CD244
22
Non-genomic actions of 1,25 dihydroxyvitamin D3 74
11.52 IFNG IFNGR1 TNF
23
MSP-RON Signaling 64
11.49 TNF TLR2 IFNG
24
THC Differentiation Pathway 64
11.49 TNF IL4 IL10 IFNGR1 IFNG
25
Th2 Differentiation 65
11.46 IL4 IL10 IFNG
26
IL-15 Signaling and its Primary Biological Effects in Different Immune Cell Types 65
Show member pathways
 11.34 TNF IL10 IFNG
27
Development and heterogeneity of the ILC family 74
11.28 TNF IL4 IL17A IFNG
28
Cytokines and inflammatory response 74
11.22 TNF IL4 IL10 IFNG
29
OX40 Pathway 64
11.18 IL4 IL10 IFNG
30
Inflammatory bowel disease signaling 74
Show member pathways
 10.87 TNF TLR2 IL4 IL10 IFNGR1 IFNG
31
Selective expression of chemokine receptors during T-cell polarization 74
10.83 IL4 IFNG
32
Immune infiltration in pancreatic cancer 74
10.79 TNF IL4 IL17A IL10 IFNG
Sources

GO Terms for Mycobacterium Tuberculosis 1

About this section

Cellular components related to Mycobacterium Tuberculosis 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.4 TNF IL17A CD244 CD209 CD1B ADA

Biological processes related to Mycobacterium Tuberculosis 1 according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.4 IFNG IFNGR1 IL4 SLC11A1 TLR2 TNF
2 positive regulation of tumor necrosis factor production GO:0032760 10.17 IFNG IFNGR1 IL17A TLR2
3 positive regulation of phagocytosis GO:0050766 10.1 TNF SLC11A1 IFNG
4 positive regulation of type II interferon production GO:0032729 10.1 TNF SLC11A1 HSPD1 CD244
5 B cell proliferation GO:0042100 10.09 IL10 HSPD1 ADA
6 positive regulation of chemokine production GO:0032722 10.08 IFNG TLR2 TNF
7 positive regulation of interleukin-10 production GO:0032733 10.06 TLR2 IL4 HSPD1
8 positive regulation of cytokine production GO:0001819 10.06 IFNG IL10 SLC11A1 TNF
9 positive regulation of osteoclast differentiation GO:0045672 10.01 TNF IL17A IFNG
10 response to lipopolysaccharide GO:0032496 9.98 TNF TLR2 SLC11A1 MAPKAPK3 IL10
11 positive regulation of amyloid-beta formation GO:1902004 9.95 TNF IFNGR1 IFNG
12 type 2 immune response GO:0042092 9.94 IL4 IL10
13 positive regulation of interleukin-23 production GO:0032747 9.94 IL17A IFNG
14 positive regulation of interleukin-18 production GO:0032741 9.93 TNF TLR2
15 neuroinflammatory response GO:0150076 9.92 IL4 IFNG
16 positive regulation of mononuclear cell migration GO:0071677 9.9 TNF IL4
17 negative regulation of cytokine production involved in immune response GO:0002719 9.89 TNF IL10
18 regulation of isotype switching GO:0045191 9.88 IL4 IL10
19 astrocyte activation GO:0048143 9.88 TNF IFNGR1 IFNG
20 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.86 TNF IFNG
21 positive regulation of interleukin-12 production GO:0032735 9.86 TLR2 IL17A IFNG HSPD1
22 positive regulation of nitrogen compound metabolic process GO:0051173 9.85 TNF IFNG
23 positive regulation of MHC class II biosynthetic process GO:0045348 9.85 IL4 IL10 IFNG
24 positive regulation of interleukin-6 production GO:0032755 9.85 TNF TLR2 IL17A IFNG HSPD1
25 chronic inflammatory response to antigenic stimulus GO:0002439 9.83 IL10 TNF
26 positive regulation of vitamin D biosynthetic process GO:0060557 9.81 IFNG TNF
27 negative regulation of amyloid-beta clearance GO:1900222 9.8 IFNG IFNGR1 TNF
28 immune response GO:0006955 9.73 CD1B CD244 IFNG IL10 IL17A IL4
29 microglial cell activation GO:0001774 9.32 TNF TLR2 IL4 IFNGR1 IFNG

Molecular functions related to Mycobacterium Tuberculosis 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.4 TNF INHA IL4 IL17A IL10 IFNG
Sources

Sources for Mycobacterium Tuberculosis 1

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....